A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours [0.03%]
一项评价NOTCH抑制剂BMS-986115在晚期实体瘤患者中安全性和耐受性的多队列I期剂量递增研究
Kyaw L Aung,Anthony B El-Khoueiry,Karen Gelmon et al.
Kyaw L Aung et al.
Background Inhibiting Notch is a promising anti-cancer strategy as it plays a critical role in cancer stem cells maintenance and tumour angiogenesis. BMS-986115 is an orally active, selective inhibitor of gamma-secretase mediated Notch sign...
Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer [0.03%]
一例胃癌患者使用纳武单抗致急性肉芽肿性间质性肾炎病例报告
Yoshihisa Nakatani,Hisato Kawakami,Masashi Ichikawa et al.
Yoshihisa Nakatani et al.
We here report a case of nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. A 68-year-old woman with recurrent gastric cancer developed acute kidney injury associated with kidney enlargement...
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis [0.03%]
纳洛妥单抗联合吉西他滨与FOLFIRINOX作为晚期胰腺癌一线化疗的比较：回顾性分析
Jihoon Kang,Inhwan Hwang,Changhoon Yoo et al.
Jihoon Kang et al.
Purpose nab-paclitaxel plus gemcitabine (AG) and FOLFIRINOX have been established as standard first-line treatment in metastatic pancreatic cancer (mPC). We performed retrospective analysis comparing the efficacies of AG and FOLFIRINOX in d...
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors [0.03%]
一项在实体瘤患者中评估口服AKT抑制剂GSK2141795的安全性、耐受性、药代动力学和药效学的I期开放标签两阶段研究
Carol Aghajanian,Katherine M Bell-McGuinn,Howard A Burris rd et al.
Carol Aghajanian et al.
Background We sought to determine the recommended phase II dose (RP2D) and schedule of GSK2141795, an oral pan-AKT kinase inhibitor. Patients and Methods Patients with solid tumors were enrolled in the dose-escalation phase. Pharmacokinetic...
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations [0.03%]
一类新的兼具NO和H2S释放的多柔比星衍生物在耐药性前列腺癌治疗中的应用及其体内体外评估研究
Elisabetta Bigagli,Cristina Luceri,Maria De Angioletti et al.
Elisabetta Bigagli et al.
Chemotherapy for castration-resistant prostate cancer (CRPC) is only temporarily effective due to the onset of chemoresistance. We investigated the efficacy of NO- and H2S-releasing doxorubicins (NitDox and H2SDox) in overcoming drug resist...
Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model [0.03%]
自噬抑制可提高十字花科蔬菜衍生的二吲哚甲烷在前列腺癌异种移植模型中的化疗效果
Hossam Draz,Alexander A Goldberg,Emma S Tomlinson Guns et al.
Hossam Draz et al.
Prostate cancer is the second leading cause of cancer-related deaths in men in North America and there is an urgent need for development of more effective therapeutic treatments against this disease. We have recently shown that diindolylmet...
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition [0.03%]
西罗莫司联合化疗可提高高危急性髓系白血病患者缓解率及mTORC1靶向抑制作用
Margaret T Kasner,Rosemarie Mick,Grace R Jeschke et al.
Margaret T Kasner et al.
Background Mammalian Target of Rapamycin Complex 1 (mTORC1) inhibitors enhance chemotherapy response in acute myelogenous leukemia (AML) cells in vitro. However whether inhibiting mTORC1 enhances clinical response to AML chemotherapy remain...
Clinical Trial
Investigational new drugs. 2018 Aug;36(4):657-666. DOI:10.1007/s10637-018-0585-x 2018
Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation [0.03%]
少见的G719S表皮生长因子受体突变获得性耐药于酪氨酸激酶抑制剂（EGFR-TKI）
Atsushi Osoegawa,Takafumi Hashimoto,Yohei Takumi et al.
Atsushi Osoegawa et al.
Background Acquired resistance (AR) to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is a common event, and several underlying mechanisms, including T790 M, MET amplification and PTEN downregulation, have been rep...
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis [0.03%]
吉西他滨前期治疗的晚期胰腺癌患者二线化疗后生存期的meta分析研究
Akiyoshi Kasuga,Yasuo Hamamoto,Ayano Takeuchi et al.
Akiyoshi Kasuga et al.
Background Post-progression survival (PPS) could be a confounding element in interpreting data from clinical trials of second-line chemotherapy in patients with advanced pancreatic cancer (PC) previously treated with gemcitabine (GEM) becau...
A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer [0.03%]
贝伐单抗联合放疗治疗局部晚期非小细胞肺癌老年患者的一项I/II期临床试验
Akihiro Tamiya,Masahiro Morimoto,Shoichi Fukuda et al.
Akihiro Tamiya et al.
Background Radiotherapy (RT) is an effective treatment for elderly patients with locally advanced non-small-cell lung cancer (NSCLC); however, no clinical trials have investigated combination RT with pemetrexed (PEM) in chemotherapy-naive p...
Clinical Trial
Investigational new drugs. 2018 Aug;36(4):667-673. DOI:10.1007/s10637-018-0587-8 2018